Tag: Agenus

Clinical Trials, Research and Development

Agenus Announces Positive Preliminary Results of iNKT Cell Therapy Trial in COVID-19

February 4, 2021

Via: BioSpace

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced positive preliminary results from its Phase 1 trial of iNKT […]